G2 Goldfields extends strike length to 1.7 km at Oko and Reports 17.8 g/t Au over 2.5 m, 9.5 g/t Au over 4.4 m, 21.1 g/t Au over 2.1 m, and 26.1 g/t Au over 1.6 m in three separate holes

G2 Goldfields extends strike length to 1.7 km at Oko and Reports 17.8 g/t Au over 2.5 m, 9.5 g/t Au over 4.4 m, 21.1 g/t Au over 2.1 m, and 26.1 g/t Au over 1

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.TORONTO, July 14, 2020 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (TSXV: GTWO) (the “Company” or “G2”) is pleased to announce multiple high-grade drilling intercepts from the Company’s ongoing drilling program at the 19,200-acre Oko-Aremu property, Region 7, Guyana.  The Company has completed 63 diamond drill holes to date, totalling 13,971 metres.  Drilling has demonstrated that within the Oko mine area high-grade gold mineralization is hosted in (i) shallow north plunging hinge zones, and (ii) in steeply dipping limbs of tightly folded carbonaceous sediments.
Highlights of recent drilling in the main Oko zone include 17.8 g/t Au over 2.5 m (OKD – 46), 9.5 g/t Au over 4.4 m (OKD – 47), as well as 21.1 g/t Au over 2.1 m and 26.1 g/t Au over 1.6 m (OKD – 48).  Significantly, a series of drill holes to the south of the main Oko zone have also encountered gold mineralization, with hole OKD – 37 intercepting multiple zones of mineralization including 7.6 g/t Au over 2.6 m.  Recent drilling demonstrates that the limits of mineralization at Oko have yet to be defined.  A list of completed drill hole locations is available at the following link https://g2goldfields.com/wp-content/uploads/2020/07/DrillHoleLocations.pdf.Oko Main Drilling ZoneDrilling in the Oko main zone continues to provide encouraging results. Several holes intercepted multiple zones of mineralization, a select list of which is available in Table 1.  A plan view of drilling completed to date at Oko with selective high-grade results is available herein as Figure 1.TABLE 1A Media Snippet accompanying this announcement is available by clicking on the image or link below:
CBJ Newsmakers

Recommended
Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.LexaGene Hires First Direct Sales Executives and announces exercise of warrants